ACRS - Aclaris Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.50
-0.09 (-0.44%)
At close: 4:00PM EDT

20.50 0.00 (0.00%)
After hours: 4:21PM EDT

Stock chart is not supported by your current browser
Previous Close20.59
Open20.56
Bid14.15 x 800
Ask25.38 x 800
Day's Range19.81 - 20.56
52 Week Range16.01 - 30.08
Volume166,883
Avg. Volume237,879
Market Cap633.573M
Beta1.56
PE Ratio (TTM)N/A
EPS (TTM)-2.94
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.29
Trade prices are not sourced from all markets
  • Aclaris' Alopecia Candidate Gets Fast Track Designation
    Zacks6 days ago

    Aclaris' Alopecia Candidate Gets Fast Track Designation

    The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.

  • GlobeNewswire7 days ago

    FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata

    The FDA’s Fast Track designation is intended to facilitate the development of new therapies for serious conditions and with the potential to address an unmet medical need. A company with an investigational medicine receiving Fast Track designation may be eligible for more frequent communications with the FDA and may receive an expedited review of the new drug application.

  • Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
    Zacks10 days ago

    Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

    Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.

  • GlobeNewswire13 days ago

    Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that on July 2, 2018 the Compensation Committee of Aclaris’ Board of Directors granted 2 non-qualified stock option awards to purchase an aggregate of 40,500 shares of its common stock and 5 restricted stock unit awards covering an aggregate of 17,300 shares of its common stock to 5 new employees under the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).

  • GlobeNewswire18 days ago

    Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced positive interim data from its Phase 2 clinical trial (AA-202 Topical) of ATI-502 for the treatment of Alopecia Totalis (AT) or Alopecia Universalis (AU), the more severe variants of Alopecia Areata (AA). ATI-502, an investigational topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502) is the most advanced topical JAK inhibitor in clinical trials for AT/AU in the United States.

  • GlobeNewswire20 days ago

    Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that the first patient has been dosed in Aclaris’ Phase 2 clinical trial of its JAK inhibitor product candidate ATI-501 oral suspension in patients with two forms of Alopecia Areata (AA) known as Alopecia Totalis (AT) and Alopecia Universalis (AU).  AA is an autoimmune dermatologic condition typically characterized by patchy non-scarring hair loss on the scalp and body. More severe forms of AA include AT, which is total scalp hair loss, and AU, which is total hair loss on the scalp and body.

  • GlobeNewswirelast month

    Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology and immunology, announced the expansion of its executive leadership team with the appointment of David Gordon, MB ChB, as Chief Medical Officer. Dr. Gordon will report to President and Chief Executive Officer, Dr. Neal Walker, and will lead Aclaris’ clinical research and medical affairs functions.  Christopher Powala, Chief Regulatory and Development Officer, has added Elaine Morefield, Ph.D to his team as Director, Product Quality.

  • GlobeNewswirelast month

    Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology, today announced the publication of the two pivotal trials leading to the FDA approval of ESKATA (hydrogen peroxide) topical solution, 40% (w/w), for the treatment of raised seborrheic keratoses (SKs) in a prestigious peer-reviewed dermatology journal, the online Journal of the American Academy of Dermatology ahead of print. The article entitled, “Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w) in patients with seborrheic keratoses: results from two identical, randomized, double-blind, placebo-controlled, Phase 3 studies (A-101-SEBK-301/302),”1 summarized the pivotal results demonstrating the safety and efficacy of ESKATA in treating raised seborrheic keratoses after one to two treatments.

  • GlobeNewswirelast month

    Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that on June 1, 2018 the Compensation Committee of Aclaris’ Board of Directors granted 3 restricted stock unit awards covering an aggregate of 7,100 shares of its common stock to 3 new employees under the Aclaris 2017 Inducement Plan.  The restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4). The 2017 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • ACCESSWIRElast month

    Wired News - Aimmune Therapeutics Presents Data from New Pan-European Study on Psychosocial Burden Associated with Peanut Allergy at EAACI Congress 2018

    LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want access to our free research report on Aimmune Therapeutics, Inc. (NASDAQ: AIMT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AIMT as the Company's latest news hit the wire. On May 30, 2018, the Company announced that it presented data from a new study on the psychosocial burden of peanut allergy in European countries at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich. Active-Investors.com is currently working on the research report for Aclaris Therapeutics, Inc. (NASDAQ: ACRS), which also belongs to the Healthcare sector as the Company Aimmune Therapeutics.

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA

    WAYNE, Pa., May 30, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...

  • GlobeNewswire2 months ago

    Landec Corporation to Nominate Two New Board Directors

    Landec Corporation (LNDC), a leading innovator of diversified health and wellness solutions within the branded natural food and CDMO markets, and Wynnefield Capital, Inc. announced today that Landec is nominating two new Board members at its Annual Shareholders Meeting in October 2018. The two new nominees are Andrew Powell, with over 12 years of public boardroom experience with global life science companies, and Nelson Obus, President and Chief Investment Officer of Wynnefield Capital. This recommendation follows a series of collaborative discussions between the Company and Wynnefield Capital, which is currently Landec’s third largest shareholder with a 9.7% position and which has held an ownership position that dates back nearly fifteen years.

  • Benzinga2 months ago

    Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

    The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting

    WAYNE, Pa., May 16, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ACRS earnings conference call or presentation 8-May-18 9:00pm GMT

    Q1 2018 Aclaris Therapeutics Inc Earnings Call

  • GlobeNewswire2 months ago

    Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting

    WAYNE, Pa., May 15, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...

  • GlobeNewswire2 months ago

    Aclaris Therapeutics to Present at the 2018 American Hair Research Summit

    Paul Changelian, Ph.D., Vice President, Biology, Aclaris Therapeutics, Inc. (ACRS), will speak at the 2018 American Hair Research Summit on “Preclinical to Clinical Translation of JAK Kinase Inhibitors" on May 15. Dr. Changelian will review the history of drug discovery targeting Janus kinase (JAK) enzymes. JAK inhibitors initially were conceived as drugs to reduce organ transplant rejection but gradually were found to have utility in autoimmune diseases and oncology.

  • GlobeNewswire2 months ago

    Aclaris Therapeutics to Attend Upcoming Investor Conferences

    WAYNE, Pa., May 10, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...

  • Associated Press2 months ago

    Aclaris: 1Q Earnings Snapshot

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 98 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

    •Management to Host Conference Call at 5:00 PM ET today. WAYNE, Pa., May 08, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing ...

  • Aclaris Therapeutics Inc (NASDAQ:ACRS): Immense Growth Potential?
    Simply Wall St.2 months ago

    Aclaris Therapeutics Inc (NASDAQ:ACRS): Immense Growth Potential?

    In December 2017, Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its most recent earnings update, which showed company earnings became less negative compared to the previous year’s level – great news forRead More...

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase by dermatologists in the United States. ESKATA is the first and only FDA-approved topical treatment for raised seborrheic keratoses (SKs) – benign skin growths that may be a cosmetic concern, especially when they appear on the face, neck or chest area.

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WAYNE, Pa., May 02, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address ...

  • GlobeNewswire3 months ago

    Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018

    WAYNE, Pa., April 24, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...

  • GlobeNewswire3 months ago

    Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee

    Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced the appointment of Bryan Reasons as a director and Chairman of the Audit Committee. Bryan Reasons has served as the Senior Vice President, Finance and Chief Financial Officer of Impax Laboratories Inc. since 2012. Prior to joining Impax, Mr. Reasons was with Cephalon, Inc., a biopharmaceutical company, serving as Vice President, Finance from 2010 to 2011 and as Vice President, Risk Management and General Auditor from 2005 to 2010.